Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu C H, Cao J, Lee J C, Lichtenstein A, Lill M, Berenson R, Berenson J
Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Bone Marrow Transplant. 1998 Jan;21(2):141-5. doi: 10.1038/sj.bmt.1701055.
Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 10(6) CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils >0.5 x 10(9)/l and platelets >20 x 10(9)/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29+/-14% and 47+/-17%. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.
55例晚期多发性骨髓瘤患者在清髓性化疗后接受了纯化的CD34选择的外周血祖细胞移植。在白消安（14mg/kg）和环磷酰胺（120mg/kg）之后，中位数为4.1×10⁶个CD34细胞/kg（范围1.2 - 30.7）被输注；使用粒细胞-巨噬细胞集落刺激因子直至造血恢复。中性粒细胞>0.5×10⁹/L和血小板>20×10⁹/L的中位时间分别为12天（范围分别为10 - 16天和8 - 184天）。移植后存活者的中位随访时间为33个月（范围7至44个月）。31例患者存活，19例无进展。中位无进展生存期为14个月。3年无进展生存率和总生存率分别为29±14%和47±17%。外周血祖细胞的CD34选择提供了有效的造血支持，并具有显著的无进展生存期和总生存期。
